CardiolRx™ Heart Drug Gains Key Validation, Offers Hope for Pericarditis

TORONTO, ON – May 07, 2026 – Cardiol Therapeutics has received a major vote of confidence from the medical community for its lead drug candidate, CardiolRx™, as results from a key study have been accepted for publication in the prestigious Journal of the American Heart Association (JAHA). The announcement validates promising data suggesting the drug could represent a paradigm shift for patients suffering from recurrent pericarditis, a painful and debilitating inflammatory heart condition.

The upcoming peer-reviewed publication provides independent validation of the Phase II MAvERIC-Pilot study, which demonstrated that CardiolRx™ led to rapid pain relief and reduced inflammation in patients with a high disease burden. This news strengthens the foundation for the company's ongoing pivotal Phase III trial, which is already more than 75% enrolled, signaling strong momentum toward a potential new treatment option.

A New Hope for a Painful Condition

Pericarditis, an inflammation of the sac-like tissue surrounding the heart, can cause debilitating chest pain, shortness of breath, and fatigue. While many patients recover from an initial episode, a significant number suffer from recurrent bouts, trapping them in a cycle of pain and uncertainty. In the United States alone, an estimated 40,000 patients experience at least one recurrence each year, with many enduring the condition for years, leading to a severely diminished quality of life, emergency room visits, and hospitalizations.

Current first-line treatments include anti-inflammatory drugs like NSAIDs and colchicine. When these fail, physicians often turn to corticosteroids. However, long-term steroid use is fraught with serious side effects and can paradoxically increase the risk of recurrence. The only FDA-approved therapy specifically for recurrent pericarditis is Rilonacept (Arcalyst), an injectable biologic. While effective, its high cost—exceeding $20,000 per month—and immunosuppressive properties often relegate it to a third-line option for the most difficult cases.

This treatment landscape leaves a significant unmet need for a safe, effective, and more accessible therapy that can break the cycle of recurrence without introducing the risks of long-term immunosuppression. CardiolRx™, an orally administered small molecule, is positioned to fill this critical gap.

Clinical Validation and Compelling Data

The results from the Phase II MAvERIC-Pilot study, soon to be detailed in JAHA, paint a compelling picture of CardiolRx™'s potential. The open-label study enrolled 27 patients with a significant history of the disease, averaging nearly six pericarditis episodes per year prior to the trial. The findings were striking.

Patients treated with CardiolRx™ experienced a rapid and sustained reduction in pain, with the median time to pain resolution or near-resolution being just five days. Inflammation, measured by C-reactive protein (CRP) levels, also dropped significantly. In 80% of patients with elevated baseline CRP, levels returned to normal within eight weeks. Most importantly, the drug appeared to break the cycle of recurrence. The average number of pericarditis episodes per year plummeted from 5.8 before the study to just 0.9 during it. A remarkable 71% of patients remained recurrence-free during an 18-week extension period. The drug also demonstrated a favorable safety profile, with high patient compliance and 89% of participants continuing into the study's extension phase.

"The upcoming publication provides important independent validation of the clinical findings generated in our Phase II MAvERIC study and further supports the potential of CardiolRx™ as a differentiated, non-immunosuppressive therapy for recurrent pericarditis," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics, in a press release. "Publication in the Journal of the American Heart Association underscores the clinical relevance of the observed reductions in pericarditis pain and inflammation, together with the favorable safety and tolerability profile demonstrated in this patient population."

The Path to Approval: Phase III and FDA Support

With strong Phase II data in hand, Cardiol Therapeutics is moving swiftly with its pivotal Phase III MAVERIC trial. The trial, which is randomized, double-blind, and placebo-controlled, is the final step required to seek regulatory approval. Its rapid enrollment, having surpassed 75% of its target, reflects significant interest from clinicians and patients and suggests an accelerated timeline toward completion.

Bolstering the drug's path forward is the Orphan Drug Designation granted by the U.S. Food and Drug Administration (FDA) in early 2024. This designation is reserved for therapies targeting rare diseases and provides significant incentives, including a potential seven years of market exclusivity upon approval, tax credits for clinical trials, and the possibility of an accelerated regulatory review. The designation signals the FDA's recognition of both the seriousness of recurrent pericarditis and the potential of CardiolRx™ to provide a meaningful clinical benefit.

While the company remains pre-revenue, a common status for a late-stage biotech, it reported having sufficient cash to fund operations into 2026. The combination of strong clinical data, rapid trial progression, and regulatory support has generated a positive outlook among many industry analysts, who see significant market potential if CardiolRx™ succeeds.

A Differentiated Scientific Approach

What sets CardiolRx™ apart is its mechanism of action. Unlike biologic drugs that block specific inflammatory messengers like interleukin-1, CardiolRx™ works by modulating the inflammasome pathway. This is a core intracellular process responsible for triggering inflammation and fibrosis in a range of heart diseases. By targeting this fundamental pathway, the drug offers a novel, non-immunosuppressive approach to taming the inflammation that drives pericarditis.

This scientific strategy is the cornerstone of Cardiol Therapeutics' broader vision. The company is also exploring CardiolRx™ for acute myocarditis—a dangerous inflammation of the heart muscle—and is developing CRD-38, a next-generation subcutaneous formulation aimed at treating heart failure. This pipeline demonstrates a focused commitment to developing anti-inflammatory and anti-fibrotic therapies for a spectrum of cardiovascular diseases. For now, all eyes are on the MAVERIC trial, which holds the potential to deliver a much-needed, accessible, and life-changing treatment for thousands of patients trapped by recurrent pericarditis.